Schedule 13G ownership disclosure

Unicycive Therapeutics, Inc.

Common Stock, $0.001 par value · CUSIP: 90466Y202

Event date: 2025-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Octagon Capital Advisors LP

    Shares: 1,000,000.00 · Class: 4.7%

  • Octagon Investments Master Fund LP

    Shares: 650,000.00 · Class: 3.0%

  • Octagon Biotech Opportunities Fund I LP

    Shares: 350,000.00 · Class: 1.7%

  • Ting Jia

    Shares: 1,000,000.00 · Class: 4.7%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001214659-26-001398
Form type
SCHEDULE 13G/A
Filer
Octagon Capital Advisors LP
CIK
CIK 1839435
Filed
Feb 10, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub